1 Jun 2015 09:00
Skyepharma to present at the Jefferies 2015 Healthcare Conference
LONDON, UK, 1 June 2015 - Skyepharma PLC (LSE SKP), the expert oral and inhalation drug development company, today announces that its CEO, Peter Grant, will present at the Jefferies 2015 Healthcare Conference in New York on Thursday, 4 June, 2015, at 8:00 a.m. Eastern Time (ET), 1:00 p.m. British Summer Time (BST).
A copy of the presentation is available on the Investor Relations section of the Skyepharma website www.skyepharma.com/Investors/Presentations_and_webcasts.
A webcast of Peter Grant's presentation will be available at wsw.com/webcast/jeff88/skp.l and via the investor relations section of Skyepharma's website.
- Ends -
For further information please contact:
Skyepharma PLC | |
Peter Grant, Chief Executive Officer Andrew Derodra, Chief Financial Officer | +44 (0)20 7881 0524 |
Jonathan Birt, Investor and Media Relations
| +44 (0)7860 361746 |
N+1 Singer | |
Shaun Dobson/Jen Boorer | +44 (0)20 7496 3000 |
FTI Consulting | |
Julia Phillips/Rob Winder/Natalie Garland-Collins | +44 (0)20 3727 1000 |
About Skyepharma PLC
Skyepharma combines proven scientific expertise with validated proprietary technologies to develop innovative oral and inhalation pharmaceutical products. The Group's licenses cover 16 approved inhalation, oral, topical and injectable products, which generate milestones, recurring royalties, and in some cases, product supply revenues. The Group also earns milestones and contract development revenues from new product developments. Products developed by Skyepharma are marketed by some of the world's most respected pharmaceutical companies. For more information, visit www.skyepharma.com